Knowing that the PI3K/AKT/mTOR pathway is hyperactive in CML, indirect suppression of mTOR function by modulation of the AMPK pathway was proposed as an alternative therapeutic approach to overcome TKI resistances. This evidence concerns the gene PRKAA2 and chronic myelogenous leukemia, BCR-ABL1 positive.